Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 1;4(10):1375-1381.
doi: 10.1001/jamaoncol.2018.2487.

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers

Skyler B Johnson  1 , Henry S Park  1 , Cary P Gross  2 , James B Yu  1   2
Affiliations

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers

Skyler B Johnson et al. JAMA Oncol. .

Abstract

Importance: There is limited information on the association among complementary medicine (CM), adherence to conventional cancer treatment (CCT), and overall survival of patients with cancer who receive CM compared with those who do not receive CM.

Objectives: To compare overall survival between patients with cancer receiving CCT with or without CM and to compare adherence to treatment and characteristics of patients receiving CCT with or without CM.

Design, setting, and participants: This retrospective observational study used data from the National Cancer Database on 1 901 815 patients from 1500 Commission on Cancer-accredited centers across the United States who were diagnosed with nonmetastatic breast, prostate, lung, or colorectal cancer between January 1, 2004, and December 31, 2013. Patients were matched on age, clinical group stage, Charlson-Deyo comorbidity score, insurance type, race/ethnicity, year of diagnosis, and cancer type. Statistical analysis was conducted from November 8, 2017, to April 9, 2018.

Exposures: Use of CM was defined as "Other-Unproven: Cancer treatments administered by nonmedical personnel" in addition to at least 1 CCT modality, defined as surgery, radiotherapy, chemotherapy, and/or hormone therapy.

Main outcomes and measures: Overall survival, adherence to treatment, and patient characteristics.

Results: The entire cohort comprised 1 901 815 patients with cancer (258 patients in the CM group and 1 901 557 patients in the control group). In the main analyses following matching, 258 patients (199 women and 59 men; mean age, 56 years [interquartile range, 48-64 years]) were in the CM group, and 1032 patients (798 women and 234 men; mean age, 56 years [interquartile range, 48-64 years]) were in the control group. Patients who chose CM did not have a longer delay to initiation of CCT but had higher refusal rates of surgery (7.0% [18 of 258] vs 0.1% [1 of 1031]; P < .001), chemotherapy (34.1% [88 of 258] vs 3.2% [33 of 1032]; P < .001), radiotherapy (53.0% [106 of 200] vs 2.3% [16 of 711]; P < .001), and hormone therapy (33.7% [87 of 258] vs 2.8% [29 of 1032]; P < .001). Use of CM was associated with poorer 5-year overall survival compared with no CM (82.2% [95% CI, 76.0%-87.0%] vs 86.6% [95% CI, 84.0%-88.9%]; P = .001) and was independently associated with greater risk of death (hazard ratio, 2.08; 95% CI, 1.50-2.90) in a multivariate model that did not include treatment delay or refusal. However, there was no significant association between CM and survival once treatment delay or refusal was included in the model (hazard ratio, 1.39; 95% CI, 0.83-2.33).

Conclusions and relevance: In this study, patients who received CM were more likely to refuse additional CCT, and had a higher risk of death. The results suggest that mortality risk associated with CM was mediated by the refusal of CCT.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Park reported receiving honoraria from Varian Medical Systems Inc and RadOncQuestions LLC. Dr Gross reported receiving research funding from 21st Century Oncology, Johnson and Johnson, Medtronic, and Pfizer. Dr Yu reported receiving research funding from 21st Century Oncology and serving as a consultant for Augmenix. No other disclosures were reported.

Figures

Figure.
Figure.. Survival of Patients Who Used Complementary Medicine vs Those Who Used No Complementary Medicine for Breast, Prostate, Lung, and Colorectal Cancer
Kaplan-Meier curve for overall survival comparing complementary medicine group with no complementary medicine group.
See this image and copyright information in PMC

Comment in

References

    1. Eisenberg DM, Davis RB, Ettner SL, et al. . Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1375-1381. doi:10.1001/jama.280.18.1569 - DOI - PubMed
    1. Engel LW, Straus SE. Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov. 2002;1(3):229-237. doi:10.1038/nrd750 - DOI - PubMed
    1. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279(19):1548-1553. doi:10.1001/jama.279.19.1548 - DOI - PubMed
    1. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015;(79):1-16. - PMC - PubMed
    1. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18(13):2505-2514. doi:10.1200/JCO.2000.18.13.2505 - DOI - PubMed